Afsheen A. Shah

Partner
Afsheen Shah

Afsheen A. Shah

Partner

LinkedIn

Afsheen Shah focuses primarily on representing hospitals, nursing homes and physician groups in negotiating a wide variety of contractual arrangements, including IT agreements, clinical research agreements, and procurement and purchasing agreements. Afsheen has also assisted multiple nursing home clients in meeting their compliance and regulatory obligations under both federal and state law and navigating government audits.  Afsheen has also assisted clients in successfully implementing and satisfying critical obligations under the requirements of corporate integrity agreements and ensuring proper compliance with applicable state and federal regulations.

Prior to joining the firm’s healthcare group, Afsheen spent 15 years representing chapter 11 debtors, creditors’ committees, individual creditors and creditor constituencies in various corporate and healthcare reorganizations and other high profile bankruptcy filings.

August 17, 2023 | Awards

38 Garfunkel Wild Attorneys Named Among the Best Lawyers in America

Thirty-Eight Garfunkel Wild attorneys were selected by their peers for inclusion in the 2024 editions of The Best Lawyers in America and The Best Lawyers: Ones to Watch.  

August 18, 2022 | Awards

35 Garfunkel Wild Attorneys Recognized In 2023 Best Lawyers In America List

Thirty Five Garfunkel Wild attorneys were selected by their peers for inclusion in the 2023 The Best Lawyers in America® guide and the Best Lawyers “Ones to Watch” list.  In addition, Partner Jason Y. Hsi was honored as “Lawyer of the Year” in the area of Litigation – Health Care Law.

August 15, 2024 | Firm News

38 Garfunkel Wild Attorneys Named in Best Lawyers in America 2025

Garfunkel Wild received prominent recognition in the 2025 editions of The Best Lawyers in America and The Best Lawyers in America: Ones to Watch. A total of 38 attorneys were honored with 59 individual recognitions across various practices and offices nationwide. Additionally, 3 Garfunkel Wild attorneys were distinguished as Lawyer of the Year, an accolade awarded to only one […]

August 21, 2025 | Firm News

31 Garfunkel Wild Attorneys Named in Best Lawyers in America 2026

Garfunkel Wild received prominent recognition in the 2026 editions of The Best Lawyers in America® and The Best Lawyers in America: Ones to Watch®. A total of 31 attorneys were honored with 47 individual recognitions across various practice areas and offices nationwide. Additionally, 1 Garfunkel Wild attorney was distinguished as Lawyer of the Year in Long Island for Litigation - Health Care, an accolade awarded to only one lawyer per practice area in each major U.S. market.

April 17, 2026 | Alerts

Another Setback for 340B Pharmacies

In the latest challenge to hospitals’ rights to use contract pharmacies, drug manufacturers targeted a Maryland law that barred them from restricting shipments of 340B drugs to contract pharmacies. In a disappointing turn for hospitals, the Fourth Circuit sided with the manufacturers and overturned a lower court ruling that had favored the state, clearing the way for the manufacturer’s unilateral restrictions to potentially move forward. This ruling contrasts earlier decisions issued by other courts, which had generally favored states who had issued laws similar to that enacted by Maryland.

April 15, 2026 | Alerts

AstraZeneca Joins Industry Shift to 340B Claims Data Reporting

In yet another escalation of data transparency requirements, AstraZeneca has joined the ranks of Eli Lilly and Novo Nordisk and announced that effective May 1, 2026, covered entities must submit pharmacy and medical claims data for all 340B purchases, including in-house pharmacy dispensations, as a condition of accessing 340B pricing.

February 12, 2026 | Podcasts

Health Care IT Contract Mistakes

In this Health Care Information and Technology Podcast, we discuss the top three health care IT contract mistakes that medical providers make and how to avoid them.

January 17, 2024 | Alerts

Favorable OIG Advisory Opinion Allows Subsidies for FDA-Approved Clinical Studies

The U.S. Department of Health and Human Services, Office of Inspector General (OIG) posted a favorable Advisory Opinion (23-11) that allows a medical device manufacturer (Manufacturer) to subsidize Medicare cost-sharing obligations as part of a U.S. Food & Drug Administration (FDA)-approved clinical study involving a Category B Investigational Device Exemption.  

December 11, 2019 | Events

Healthcare Financial Management Association’s (HFMA) Metropolitan New York Chapter Regulatory Compliance Seminar

Afsheen A. Shah will present at the Healthcare Financial Management Association’s (Hfma) Metropolitan New York Chapter Regulatory Compliance Seminar December 11, 2019.

Additional speaking & writing

Speeches and Events

  • Speaker – National Employment Lawyers Association, Fall Conference “A Bankruptcy Overview for the Employment Litigator. (October 23, 2020)
  • When a Small Case Becomes a Big Case: Keeping E-Discovery Cost in Check” (South Asian Bar Association of North America (SABA North America) Annual Conference, New York, NY (June 29, 2018)

Publications

  • Authored chapter entitled “Regulated Medical Waste” and co-authored “Committee for Physicians’ Health and Physician Impairment” in the Legal Manual of New York Physicians (Sixth Edition)
  • The Hazards of Pharmaceutical Disposal: Rising Issues of Concern for Healthcare, HFMA’s New Jersey Chapter Garden State Focus, November/December 2010, Vol 57, Number 3

Afsheen Shah focuses primarily on representing hospitals, nursing homes and physician groups in negotiating a wide variety of contractual arrangements, including IT agreements, clinical research agreements, and procurement and purchasing agreements. Afsheen has also assisted multiple nursing home clients in meeting their compliance and regulatory obligations under both federal and state law and navigating government audits.  Afsheen has also assisted clients in successfully implementing and satisfying critical obligations under the requirements of corporate integrity agreements and ensuring proper compliance with applicable state and federal regulations.

Prior to joining the firm’s healthcare group, Afsheen spent 15 years representing chapter 11 debtors, creditors’ committees, individual creditors and creditor constituencies in various corporate and healthcare reorganizations and other high profile bankruptcy filings.

January 17, 2024

Favorable OIG Advisory Opinion Allows Subsidies for FDA-Approved Clinical Studies

The U.S. Department of Health and Human Services, Office of Inspector General (OIG) posted a favorable Advisory Opinion (23-11) that allows a medical device manufacturer (Manufacturer) to subsidize Medicare cost-sharing obligations as part of a U.S. Food & Drug Administration (FDA)-approved clinical study involving a Category B Investigational Device Exemption.  

December 11, 2019

Healthcare Financial Management Association’s (HFMA) Metropolitan New York Chapter Regulatory Compliance Seminar

Afsheen A. Shah will present at the Healthcare Financial Management Association’s (Hfma) Metropolitan New York Chapter Regulatory Compliance Seminar December 11, 2019.

February 12, 2026

Health Care IT Contract Mistakes

In this Health Care Information and Technology Podcast, we discuss the top three health care IT contract mistakes that medical providers make and how to avoid them.

April 15, 2026

AstraZeneca Joins Industry Shift to 340B Claims Data Reporting

In yet another escalation of data transparency requirements, AstraZeneca has joined the ranks of Eli Lilly and Novo Nordisk and announced that effective May 1, 2026, covered entities must submit pharmacy and medical claims data for all 340B purchases, including in-house pharmacy dispensations, as a condition of accessing 340B pricing.

April 17, 2026

Another Setback for 340B Pharmacies

In the latest challenge to hospitals’ rights to use contract pharmacies, drug manufacturers targeted a Maryland law that barred them from restricting shipments of 340B drugs to contract pharmacies. In a disappointing turn for hospitals, the Fourth Circuit sided with the manufacturers and overturned a lower court ruling that had favored the state, clearing the way for the manufacturer’s unilateral restrictions to potentially move forward. This ruling contrasts earlier decisions issued by other courts, which had generally favored states who had issued laws similar to that enacted by Maryland.

April 17, 2026|Alerts

Another Setback for 340B Pharmacies

In the latest challenge to hospitals’ rights to use contract pharmacies, drug manufacturers targeted a Maryland law that barred them from restricting shipments of 340B drugs to contract pharmacies. In a disappointing turn for hospitals, the Fourth Circuit sided with the manufacturers and overturned a lower court ruling that had favored the state, clearing the way for the manufacturer’s unilateral restrictions to potentially move forward. This ruling contrasts earlier decisions issued by other courts, which had generally favored states who had issued laws similar to that enacted by Maryland.

April 15, 2026|Alerts

AstraZeneca Joins Industry Shift to 340B Claims Data Reporting

In yet another escalation of data transparency requirements, AstraZeneca has joined the ranks of Eli Lilly and Novo Nordisk and announced that effective May 1, 2026, covered entities must submit pharmacy and medical claims data for all 340B purchases, including in-house pharmacy dispensations, as a condition of accessing 340B pricing.

February 12, 2026|Podcasts

Health Care IT Contract Mistakes

In this Health Care Information and Technology Podcast, we discuss the top three health care IT contract mistakes that medical providers make and how to avoid them.

January 17, 2024|Alerts

Favorable OIG Advisory Opinion Allows Subsidies for FDA-Approved Clinical Studies

The U.S. Department of Health and Human Services, Office of Inspector General (OIG) posted a favorable Advisory Opinion (23-11) that allows a medical device manufacturer (Manufacturer) to subsidize Medicare cost-sharing obligations as part of a U.S. Food & Drug Administration (FDA)-approved clinical study involving a Category B Investigational Device Exemption.  

December 11, 2019|Events

Healthcare Financial Management Association’s (HFMA) Metropolitan New York Chapter Regulatory Compliance Seminar

Afsheen A. Shah will present at the Healthcare Financial Management Association’s (Hfma) Metropolitan New York Chapter Regulatory Compliance Seminar December 11, 2019.

Additional speaking & writing

Speeches and Events

  • Speaker – National Employment Lawyers Association, Fall Conference “A Bankruptcy Overview for the Employment Litigator. (October 23, 2020)
  • When a Small Case Becomes a Big Case: Keeping E-Discovery Cost in Check” (South Asian Bar Association of North America (SABA North America) Annual Conference, New York, NY (June 29, 2018)

Publications

  • Authored chapter entitled “Regulated Medical Waste” and co-authored “Committee for Physicians’ Health and Physician Impairment” in the Legal Manual of New York Physicians (Sixth Edition)
  • The Hazards of Pharmaceutical Disposal: Rising Issues of Concern for Healthcare, HFMA’s New Jersey Chapter Garden State Focus, November/December 2010, Vol 57, Number 3
Education
J.D.,
Hofstra University School of Law,
1998,
  • Dean’s List
,


B.A.,
University of North Carolina at Chapel Hill,
1995,
  • Dean’s List
,
Bar Admissions

New York

Court admissions

New York Supreme Court, Appellate Division

U.S. District Court: Southern District of New York

U.S. District Court: Eastern District of New York

U.S. Court of Appeals: Second Circuit

PROFESSIONAL MEMBERSHIPS
  • New York State Bar Association
  • Member of the American Bar Association Advisory Panel
AWARDS & RANKINGS
  • Best Lawyers in America® – Health Care Law (2023-2026)
  • New York Super Lawyers – Rising Stars (2013)